Waltham, MA, United States of America

Parika Petaipimol

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Upstream Bio, Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Parika Petaipimol. Retrieved from https://idiyas.com/inventor/parika-petaipimol

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Parika Petaipimol: Innovator in Pharmaceutical Compositions

Introduction

Parika Petaipimol is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that target the human TSLP receptor.

Latest Patents

Petaipimol holds a patent for "Pharmaceutical compositions comprising anti-human TSLP receptor antibodies and methods of using the same." This patent details pharmaceutical compositions that include an anti-TSLP-R antibody or an antigen-binding fragment, along with a pharmaceutically acceptable buffer, excipient, and surfactant. These compositions are designed for various therapeutic applications.

Career Highlights

Currently, Parika Petaipimol is associated with Upstream Bio, Inc., where he continues to advance his research and development efforts. His work focuses on innovative solutions in the pharmaceutical industry, contributing to the understanding and treatment of various conditions.

Collaborations

Some of his notable coworkers include Robert Patrick Gearing and Bingquan Wang, who collaborate with him on various projects within the company.

Conclusion

Parika Petaipimol's contributions to pharmaceutical innovations highlight his role as a key inventor in the field. His work on anti-TSLP receptor antibodies represents a significant advancement in therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…